Literature DB >> 2305009

Sleep laboratory investigations on hypnotic properties of melatonin.

F Waldhauser1, B Saletu, I Trinchard-Lugan.   

Abstract

Melatonin (MLT), a pineal hormone, has some sedative and hypnotic properties. To explore this effect further 20 young, healthy volunteers exposed to artificial insomnia participated in a double-blind, placebo controlled, parallel group design study. They slept in a sleep laboratory for several consecutive nights and were polygraphically monitored and subjected to a battery of psychometric tests and standardized self-report questionnaires each morning. One night all subjects received only placebo (21:00 hours) and on a second night half of them were subjected to placebo and half to MLT. On the later night blood MLT levels were measured. Polygraphic recordings revealed that MLT at bedtime decreased the time the subjects were awake before sleep onset (P less than 0.025), sleep latency (P less than 0.05), and the number of awakenings during the total sleep period (P less than 0.025), and increased sleep efficiency (P less than 0.05). In addition, it decreased sleep stage 1 (P less than 0.05) and increased sleep stage 2 (P less than 0.025). On the morning following the treatment most objective and subjective measures for awakening quality showed a trend towards improvement after MLT. One hour after its oral administration, serum MLT rose to a high pharmacological level (25817 pg/ml; median), but individual peak serum MLT levels varied by a factor of 300.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305009     DOI: 10.1007/bf02244410

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

1.  Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard.

Authors:  T Hori; Y Sugita; E Koga; S Shirakawa; K Inoue; S Uchida; H Kuwahara; M Kousaka; T Kobayashi; Y Tsuji; M Terashima; K Fukuda; N Fukuda
Journal:  Psychiatry Clin Neurosci       Date:  2001-06       Impact factor: 5.188

2.  On the effects of melatonin on sleep and behavior in man.

Authors:  H Cramer; J Rudolph; U Consbruch; K Kendel
Journal:  Adv Biochem Psychopharmacol       Date:  1974

3.  Natural and melatonin-induced sleep in young chickens--a behavioral and electrographic study.

Authors:  Y Hishikawa; H Cramer; W Kuhlo
Journal:  Exp Brain Res       Date:  1969       Impact factor: 1.972

4.  Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise.

Authors:  B Saletu; G Kindshofer; P Anderer; J Grünberger
Journal:  Int J Clin Pharmacol Res       Date:  1987

5.  Plasma concentrations of melatonin in man following oral absorption of different preparations.

Authors:  M Aldhous; C Franey; J Wright; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

6.  Nocturnal traffic noise, sleep, and quality of awakening: neurophysiologic, psychometric, and receptor activity changes after quazepam.

Authors:  B Saletu; J Grünberger; W Sieghart
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

7.  Acute pharmacology of melatonin.

Authors:  J Barchas; F DaCosta; S Spector
Journal:  Nature       Date:  1967-05-27       Impact factor: 49.962

8.  Traffic noise-induced sleep disturbances and their correction by an anxiolytic sedative, OX-373.

Authors:  B Saletu; J Grünberger
Journal:  Neuropsychobiology       Date:  1981       Impact factor: 2.328

9.  The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study.

Authors:  J Arendt; A A Borbely; C Franey; J Wright
Journal:  Neurosci Lett       Date:  1984-04-06       Impact factor: 3.046

10.  Effects of melatonin on sleep and neurochemistry in the rat.

Authors:  S W Holmes; D Sugden
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

View more
  27 in total

1.  Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Authors:  Jared Minkel; Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2013-09-01

2.  Low dose melatonin improves sleep in healthy middle-aged subjects.

Authors:  M E Attenburrow; P J Cowen; A L Sharpley
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

Review 3.  Melatonin, sleep, aging, and the health protection branch.

Authors:  S N Young
Journal:  J Psychiatry Neurosci       Date:  1996-05       Impact factor: 6.186

4.  An endogenous 5-HT(7) receptor mediates pigment granule dispersion in Xenopus laevis melanophores.

Authors:  M T Teh; D Sugden
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Effect of pharmacological daytime doses of melatonin on human mood and performance.

Authors:  A B Dollins; H J Lynch; R J Wurtman; M H Deng; K U Kischka; R E Gleason; H R Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

7.  Ramelteon for the treatment of insomnia in menopausal women.

Authors:  Roseanne DeFronzo Dobkin; Matthew Menza; Karina L Bienfait; Lesley A Allen; Humberto Marin; Michael A Gara
Journal:  Menopause Int       Date:  2009-03

Review 8.  Light, melatonin and the sleep-wake cycle.

Authors:  G M Brown
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

9.  Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans.

Authors:  Shantha M W Rajaratnam; Benita Middleton; Barbara M Stone; Josephine Arendt; Derk-Jan Dijk
Journal:  J Physiol       Date:  2004-09-30       Impact factor: 5.182

10.  Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease.

Authors:  Glenna A Dowling; Robert L Burr; Eus J W Van Someren; Erin M Hubbard; Jay S Luxenberg; Judy Mastick; Bruce A Cooper
Journal:  J Am Geriatr Soc       Date:  2007-12-07       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.